Sociedad Americana de Hirudoterapia

The Hirudo medicinalis microbiome is a source of new antimicrobial peptides

Basic science / drug discovery published in Int J Mol Sci (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryResistencia antimicrobianaDesarrollo de fármacosGenómica y proteómicaGrafskaia E et al. · International journal of molecular sciences, 2020

Abstract

Antimicrobial peptides (AMPs) are considered a promising new class of anti-infectious agents. This study reports new antimicrobial peptides derived from the Hirudo medicinalis microbiome identified by a computational analysis method applied to the H. medicinalis metagenome. The identified AMPs possess a strong antimicrobial activity against Gram-positive and Gram-negative bacteria (MIC range: 5.3 to 22.4 μM), including Staphylococcus haemolyticus, an opportunistic coagulase-negative pathogen. The secondary structure analysis of peptides via CD spectroscopy showed that all the AMPs except pept_352 have mostly disordered structures that do not change under different conditions. For peptide pept_352, the α-helical content increases in the membrane environment. The examination of the mechanism of action of peptides suggests that peptide pept_352 exhibits a direct membranolytic activity. Furthermore, the cytotoxicity assay demonstrated that the nontoxic peptide pept_1545 is a promising candidate for drug development. Overall, the analysis method implemented in the study may serve as an effective tool for the identification of new AMPs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesCell LineCell SurvivalCircular DichroismDrug DiscoveryFibroblastsGram-Negative BacteriaGram-Positive BacteriaHirudo medicinalis

Resumen

Computational metagenomic mining of Hirudo medicinalis microbiome identifying novel antimicrobial peptides with strong activity (MIC 5.3-22.4 uM) against Gram-positive and Gram-negative bacteria including coagulase-negative pathogens.

Por qué esto importa para la hirudoterapia

This study used a computational analysis of the Hirudo medicinalis metagenome to identify new antimicrobial peptides (AMPs) derived from the medicinal leech microbiome, finding strong activity against both Gram-positive and Gram-negative bacteria (MIC range 5.3–22.4 μM) including the opportunistic pathogen Staphylococcus haemolyticus. One peptide (pept_352) exhibited direct membranolytic activity, while another (pept_1545) was found nontoxic in a cytotoxicity assay and identified as a promising candidate for drug development. This work is relevant to ASH's domain as it characterizes antimicrobial compounds associated with Hirudo medicinalis, the medicinal leech. The caveat is that the study is preclinical and in-vitro in nature; no animal or human testing is described, and clinical efficacy remains unestablished.

Citación

The Hirudo medicinalis microbiome is a source of new antimicrobial peptides.

Grafskaia E et al. · International journal of molecular sciences, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.